ACT
(Fluoride)Phase 3Small molecule
GSKFluoride is used to strengthen tooth enamel and prevent tooth decay by making teeth more resistant to acid attacks from bacteria and sugars in the mouth.[1] ACT is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
ACT is one of 133 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.
7
Indications
27
Total Trials
0
Active Trials
132
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
274 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Kerendia
BayerPhase 3
ACT
GSKPhase 3
Inpefa
LLexicon Pharmaceuticals
Phase 3
Retatrutide
Eli LillyPhase 3
Vicadrostat
Boehringer IngelheimPhase 3
Repatha
AmgenPreclinical
Farxiga
AstraZenecaPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Mounjaro
Eli LillyPreclinical
Praluent
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Plaque5 trials
Efficacy4 trials
Gingivitis2 trials
Fluoride2 trials
11 more indications
White Spot Lesions2 trials
Prevention of White Spot Lesions Using Bioactive Gel
Unknown status·—·Phase 1·NCT05948228·330 enrolled
Effectiveness1 trial
Treatment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fluoride. EMBL-EBI & Wellcome Sanger Institute.
- [4]